LymeDiseaseUpdate

…challenges of Lyme disease diagnosis and the sensitivities and specificities of both clinical features and laboratory tests. In conjunction with its companion paper on the epidemiology of Lyme disease (Purple…

FINAL_Extended Dose Intervals_EN_

…and RSS feeds are available: https://www.canada.ca/en/public- health/corporate/stay-informed-stay-connected/public-health-updates/subscribe.html 9 http://www.canada.ca/naci https://www.canada.ca/en/public-health/services/canadian-immunization-guide.html https://www.canada.ca/en/public-health/corporate/stay-informed-stay-connected/public-health-updates/subscribe.html NACI Statement Development Timeline 10 December 2020 • First COVID- 19 vaccines approved • NACI begins providing evidence based…

IQ_EP22_Resource3

…for comparisons of categorical data; and Student’s t-test or U of Mann- Whitney for quantitative variables, according to the normal distribution or not. To compare the epidemiological and microbiology results…

Keynan STBBI POCT Realist Review Feb 4 2020

…Relias Media. 2009. p. 46–8. Available from: https://www.reliasmedia.com/articles/112422-reach-at-risk-youth-with- rapid-hiv-tests?v=preview 113. Gwadz M V, Cleland CM, Quiles R, Nish D, Welch J, Michaels LS, et al. CDC HIV testing guidelines and…

Final Indicators Dashboard (1)

…demonstrated understanding and skill in cultural competency and ability to communicate in languages of the community including sign language. 43. The public health agency has access to communications personnel that…

Indicators Dashboard February 4 – Colors

…to or targeted for communities and individuals that experience disadvantage. 45. The public health agency communication strategy includes plans and/or procedures for ensuring cultural competency and/or sensitivity to impacted communities…

H1N1_vaccine

…apart HI ≥40 after 1st dose: i) 45 (7.5-) 50 (15-) N/A (30-) ii) 69 (7.5-) 75 (15-) N/A (30-) iii) 95 (7.5-) 98 (15-) 100 (30-) iv) 94 (7.5-)…

H1N1_vaccine

…apart HI ≥40 after 1st dose: i) 45 (7.5-) 50 (15-) N/A (30-) ii) 69 (7.5-) 75 (15-) N/A (30-) iii) 95 (7.5-) 98 (15-) 100 (30-) iv) 94 (7.5-)…

Global_Burden_Disease_Influenza_ENG

…sexes and for 187 countries (3). YLLs were calculated from age-, sex-, country-, and time-specif- ic mortality by cause. YLDs were calculated as prevalence for 1,160 disabling sequelae, by age…